MDR-TB drugs in

pregnancy

Jennifer Hughes, MD TB Scientific Committee meeting 27 Oct 2023

Desmond Tutu TB Centre, Stellenbosch University, CRS 31790








2

Prevalence of TB in pregnancy

10.6 million new diagnoses of active TB





TB burden during pregnancy is likely high but not well quantified

00

RR/MDR-TB????

Urgent need for surveillance and reporting

TB incidence peaks during the reproductive age, irrespective of HIV status

Women in sub-Saharan Africa

Deluca JAIDS 2009


Women in India

RNTCP Gender differentials in TB control 2004

26-30

31-35

36-40






Slide, courtesy, Amita Gupta

Increased adverse outcomes with TB during pregnancy

4



Includes: 3,384 pregnancies with active TB and 119,448 without TB



WHO RR-TB treatment guidance 2022

Table A. List of recommendations in the 2022 update, where (a) is a new recommendation based on review of the new evidence and (b) is a reprinted recommendation where no new evidence was available or searched for the review.

1. The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen for MDR/RR-TB and pre-XDR-TB (a)

WHO suggests the use of the 6-month treatment regimen composed of bedaquiline, 11 pretomanid, linezolid (600 mg) and moxifloxacin (BPaLM) rather than 9-month or longer (18-month) regimens in MDR/RR-TB patients.

(Conditional recommendation, very low certainty of evidence)

2. The 9-month all-oral regimen for MDR/RR-TB (a)

21 WHO suggests the use of the 9-month all-oral regimen rather than longer (18-month) regimens in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded

(Conditional recommendation, very low certainty of evidence)

3. Longer regimens for MDR/RR-TB (b)

5

In multidrug - or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer 31 regimens, all three Group A agents and at least one Group B agent should be induded to ensure that treatment starts with at least four TB agents likely to be effective, and that at least three agents are included for the rest of the treatment if bedaquiline is stopped. If only one or two Group A agents are used, both Group B agents are to be included. If the regimen cannot be composed with agents from Groups A and B alone, Group C agents are added to complete it.

(Conditional recommendation, very low certainty of evidence)



Group A: BDQ / LZD / FLQ

Other: Pretomanid



Group A: BDQ / LZD / FLQ Group B: CFZ Group C: PZA / EMB Other: high dose INH



Group A: BDQ / LZD / FLQ Group B: CFZ / CS Group C: *(if options are limited)*

Existing peri-partum PK data for WHO Groups A & B drugs among people treated for RR-TB

6

WHO Group Drug Name	Group A Fluoroquinolones	Group A Bedaquiline	Group A Linezolid	Group B Clofazimine	Group B Terizidone
During pregnancy	Moxi: ♀ (n=1) PK at 2T and 3T _{Van Kampenhout 2017}	♀♀♀♀♀♀♀♀ ♀♀♀♀ (n=13) <i>PK at</i> ≥ 28 <i>wks</i> <i>Court 2022</i>	♀ (n=1) PK at 2T and 3T _{Van Kampenhout 2017}		
Post-partum	Moxi: ♀ (n=1) PK at 8 wks PP ^{Van Kampenhout 2017}	♀♀♀♀♀♀♀ (n=6) <i>PK at 6 wks PP</i> <i>Court 2022</i>	♀ (n=1) PK at 8 wks PP _{Van Kampenhout 2017}		
Breastmilk and foetal transfer		FT:			
Safety	?? risk to foetus Assoc. with LBW	Sig. BM transfer Assoc. with LBW	Incr. exposures 2T \rightarrow 3T \rightarrow PP		

Recent / current PK studies of TB drugs in pregnancy

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and						
Postpartum	IMPAACT 2026 (preceded by P1026s)					
ClinicalTrials.gov ID I NCT04518228						
Sponsor ① National Institute of Allergy and Infectious Diseases (NIAID)						
Information provided by () National Institute of Allergy and Infectious Diseases (NIAID) (Responsible Party)						
Last Update Posted 1 2023-01-05						

- Sub-study of BEAT Tuberculosis (South Africa) NCT04062201
- Observational cohort study in KZN, South Africa
- Others? (Not published or on clinicaltrials.gov)




WHO GROUP	TB MEDICINE		Antimicrobial drugs contraindicated				
Group A	Levofloxacin or Moxifloxacin	RR-TB is	in Pregnancy				
Associated with better outcomes and mortality	Bedaquiline	treated for	Sulfonamides Aminoglycosides				
benefit	Linezolid	6-18 mths	Fluoroquinolones Erythromycin				
Group B	Clofazimine	with 4-5	Metronidazole Tetracyclines				
Associated with better outcomes	Cycloserine / Terizidone effective drugs		Ribavirin Griseofulvin Chloramphenicol				
Group C Potentially effective	Ethambutol, delamanid, pyrazinamide, carbapenems, amikacin, ethionamide, PAS	ulugs	MED (NAZ				
2T (20-26 weeks) 3T (30-38 weeks) Delivery 2-8 weeks post-partum							
p	Intensive PK sampler re-dose and 0, 2, 4, 6, 8, 12 he	-	(P1026s)				
	LFX plasma concentrations measured with HPLC TMSA						

Levofloxacin non-compartmental analysis results						
Pharmacokinetic	Second trimester	Third trimester (3T)	Post-partum (PP)	2T vs PP (n = 4)	3T vs PP (n = 7)	
parameters	(2T)	(n = 10) Median [Q1,	(n = 8) Median [Q1,	GMR [90% CI]	GMR [90% CI]	
	(n = 6) Median [Q1,	Q3]	Q3]			
	Q3]					
C _{max} (μg/mL)	10.31	10.55	10.61	0.86	0.98	
	[9.33, 12.10]	[7.71, 11.00]	[8.20, 12.70]	[0.59, 1.25]	[0.85, 1.12]	
C _{min} (μg/mL)	0.94	1.45	1.41	0.72	1.23	
	[0.85, 1.03]	[0.04, 1.59]	[0.16, 1.72]	[0.17, 3.00]	[0.24, 6.23]	
AUC ₀₋₁₂	69.01	77.64	80.23	0.75	0.94	
(µg*h/mL)	[60.12, 77.14]	[70.51, 85.05]	[71.80, 97.73]	[0.60, 0.95]	[0.81, 1.08]	
T _{1/2} (h)	6.28	8.71	8.17	0.84	1.11	
	[5.71, 6.64]	[5.95, 10.19]	[6.42, 9.30]	[0.73, 0.97]	[0.83, 1.50]	
CL/F (litres/hr)	13.43	12.88	11.38	1.33	1.07	
	[12.03, 15.45]	[11.76, 14.18]	[9.96, 13.64]	[1.05, 1.67]	[0.93, 1.23]	
Vd/F (litres)	108.92	167.86	134.96	1.12	1.16	
	[97.39, 159.31]	[114.44, 206.86]	[107.44, 198.01]	[0.86, 1.44]	[0.79, 1.72]	

Cmax = maximum concentration; Cmin = minimum concentration; AUC = area under the curve; $T_{1/2}$ = half life; CL/F = clearance; Vd/F = volume of distribution; 2T = second trimester; Q1 = first quartile; Q3 = third quartile; 3T = third trimester; PP = post-partum; GMR = geometric mean ratio

10 Sociobehavioural research

"What challenges do you encounter in accessing healthcare services while pregnant with RR-TB?"



What are the perceptions, attitudes, beliefs, experiences and preferences of people receiving RR-TB treatment during pregnancy and post-partum?

"What advice would you give to other people diagnosed with RR-TB while pregnant?"

- RR-TB diagnosed before vs after pregnancy test
- Stigma associated with RR-TB highlighted during pregnancy





11



THANKS!



Next steps: PK and safety 1026S: CFZ, MFX, Linezolid, BDQ: NCA and modeling

Any questions?

You can find me at

jhughes@sun.ac.za

